Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial

Johannes Zacherl, Aviel Roy-Shapira, Luigi Bonavina, Amol Bapaye, Ralf Kiesslich, Sebastian F Schoppmann, William R Kessler, Don J Selzer, Ryan C Broderick, Glen A Lehman, Santiago Horgan, Johannes Zacherl, Aviel Roy-Shapira, Luigi Bonavina, Amol Bapaye, Ralf Kiesslich, Sebastian F Schoppmann, William R Kessler, Don J Selzer, Ryan C Broderick, Glen A Lehman, Santiago Horgan

Abstract

Background: Both long-term proton pump inhibitor (PPI) use and surgical fundoplication have potential drawbacks as treatments for chronic gastroesophageal reflux disease (GERD). This multi-center, prospective study evaluated the clinical experiences of 69 patients who received an alternative treatment: endoscopic anterior fundoplication with a video- and ultrasound-guided transoral surgical stapler.

Methods: Patients with well-categorized GERD were enrolled at six international sites. Efficacy data was compared at baseline and at 6 months post-procedure. The primary endpoint was a ≥ 50 % improvement in GERD health-related quality of life (HRQL) score. Secondary endpoints were elimination or ≥ 50 % reduction in dose of PPI medication and reduction of total acid exposure on esophageal pH probe monitoring. A safety evaluation was performed at time 0 and weeks 1, 4, 12, and 6 months.

Results: 66 patients completed follow-up. Six months after the procedure, the GERD-HRQL score improved by >50 % off PPI in 73 % (48/66) of patients (95 % CI 60-83 %). Forty-two patients (64.6 %) were no longer using daily PPI medication. Of the 23 patients who continued to take PPI following the procedure, 13 (56.5 %) reported a ≥ 50 % reduction in dose. The mean percent of total time with esophageal pH <4.0 decreased from baseline to 6 months (P < 0.001). Common adverse events were peri-operative chest discomfort and sore throat. Two severe adverse events requiring intervention occurred in the first 24 subjects, no further esophageal injury or leaks were reported in the remaining 48 enrolled subjects.

Conclusions: The initial 6-month data reported in this study demonstrate safety and efficacy of this endoscopic plication device. Early experience with the device necessitated procedure and device changes to improve safety, with improved results in the later portion of the study. Continued assessment of durability and safety are ongoing in a three-year follow-up study of this patient group.

Trial registration: ClinicalTrials.gov NCT00734747.

Figures

Fig. 1
Fig. 1
A–C Medigus transoral surgical stapler: A Full flexible endostapler, OD 15.5 mm B Distal tip C positioning of cartridge 3 cm proximal to gastroesophageal junction for stapling
Fig. 2
Fig. 2
Step by step endoscopic images of a procedure involving the placement of three quintuplets of staples (15 staples total) to create an effective gastroesophageal flap valve
Fig. 3
Fig. 3
Boxplots of GERD-HRQL median scores at baseline (N = 66) and 6 months post-procedure (N = 64)

References

    1. Dent J, Holloway RH, Toouli J, Dodds WJ. Mechanisms of lower oesophageal sphincter incompetence in patients with symptomatic gastrooesophageal reflux. Gut. 1988;29:1020–1028. doi: 10.1136/gut.29.8.1020.
    1. Tack J, Becher A, Mulligan C, Johnson DA. Systematic review: the burden of disruptive gastro-oesophageal reflux disease on health-related quality of life. Aliment Pharmacol Ther. 2012;35:1257–1266. doi: 10.1111/j.1365-2036.2012.05086.x.
    1. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs. 2007;67:1521–1530. doi: 10.2165/00003495-200767110-00001.
    1. Lu M, Malladi V, Agha A, Abydayyeh S, Han C, Siepman N, Graham DY. Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. Dig Dis Sci. 2007;2052:2813–2820. doi: 10.1007/s10620-007-9811-7.
    1. Clayton SB, Rife CC, Singh ER, Kalbfleisch JH, Castell DO. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing. Dis Esophagus. 2012;25:682–686. doi: 10.1111/j.1442-2050.2011.01310.x.
    1. Milkes D, Gerson LB, Triadafilopoulos G. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal and intragastric pH in patients with gastroesophageal reflux disease (GERD) Am J Gastroenterol. 2004;99:991–996. doi: 10.1111/j.1572-0241.2004.30124.x.
    1. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. Clin Outcomes Manag. 2000;7:29–34.
    1. Gallup Organization . The 2000 gallup study of consumers’ use of stomach relief products. Princeton: Gallup Organization; 2000.
    1. Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419–1425. doi: 10.1038/ajg.2011.146.
    1. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol. 2004;2:665–668. doi: 10.1016/S1542-3565(04)00289-7.
    1. Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009;25:1869–1878. doi: 10.1185/03007990903035745.
    1. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398–1402. doi: 10.1136/gut.2005.087668.
    1. Bytzer P, Zanten SV, Mattsson H, Wernersson B. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis: a post hoc analysis of 5796 patients. Aliment Pharmacol Ther. 2012;36:635–643. doi: 10.1111/apt.12007.
    1. Johnson DA, Oldfield EC., 4th Reported side effects and complications of long-term proton pump inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol. 2013;11:458–464. doi: 10.1016/j.cgh.2012.11.031.
    1. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124:519–526. doi: 10.1016/j.amjmed.2011.01.007.
    1. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310:2435–2442. doi: 10.1001/jama.2013.280490.
    1. Kellokumpu L, Voutilainen M, Haglund C, Färkkilä M, Roberts PJ, Kautiainen H. Quality of life following laparoscopic Nissen fundoplication: assessing short-term and long-term outcomes. World J Gastroenterol. 2013;19:2818–3810. doi: 10.3748/wjg.v19.i24.3810.
    1. Broeders JA, Roks DJ, Ahmed Ali U, Watson DI, Baigrie RJ, Cao Z, Hartmann J, Maddern GJ. Laparoscopic anterior 180-degree versus Nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg. 2013;257:850–859. doi: 10.1097/SLA.0b013e31828604dd.
    1. Klaus A, Hinder RA, DeVault KR, Achem SR. Bowel dysfunction after laparoscopic antireflux surgery: incidence, severity, and clinical course. Am J Med. 2003;114:6–9. doi: 10.1016/S0002-9343(02)01301-3.
    1. Bowrey DJ, Blom D, Crookes PF, Bremner CG, Johansson JL, Lord RV, Peters JH. Risk factors and the prevalence of trocar site herniation after laparoscopic fundoplication. Surg Endosc. 2001;15:663–666. doi: 10.1007/s004640080146.
    1. Kauer WK, Roy-Shapira A, Watson D, Sonnenschein M, Sonnenschein E, Unger J, Voget M, Stein HJ. Preclinical trial of a modified gastroscope that performs a true anterior fundoplication for the endoluminal treatment of gastroesophageal reflux disease. Surg Endosc. 2009;23:2728–2731. doi: 10.1007/s00464-009-0479-2.
    1. Velanovich V. The development of the GERD-HRQL symptom severity instrument. Dis Esophagus. 2007;20:130–13423. doi: 10.1111/j.1442-2050.2007.00658.x.
    1. Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE., 2nd The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc. 1996;44:541–547. doi: 10.1016/S0016-5107(96)70006-8.
    1. Jamieson JR, Stein HJ, DeMeester TR, Bonavina L, Schwizer W, Hinder RA, Albertucci M. Ambulatory 24-h esophageal pH monitoring: normal values, optimal thresholds, specificity, sensitivity, and reproducibility. Am J Gastroenterol. 1992;87:1102–1111.
    1. Cadiere GB, Rajan A, Germay O, et al. Endoluminal fundoplication by a transoral device for the treatment of GERD: a feasibility study. Surg Endosc. 2008;22:333–342. doi: 10.1007/s00464-007-9618-9.
    1. Cadière GB, Buset M, Muls V, Rajan A, Rösch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Devière J. Antireflux transoral incisionless fundoplication using esophyX: 12-month results of a prospective multicenter study. World J Surg. 2008;32:1676–1688. doi: 10.1007/s00268-008-9594-9.
    1. Locke GR, 3rd, Horwhat J, Mashimo H, Savarino E, Zentilin P, Savarino V, Zerbib F, Armbruster SP, Wong RK, Moawad F. Endotherapy for and tailored approaches to treating GERD, and refractory GERD. Ann N Y Acad Sci. 2013;1300:166–186. doi: 10.1111/nyas.12240.
    1. Lipham JC, DeMeester TR, Ganz RA, Bonavina L, Saino G, Dunn DH, Bemelman W. The LINX® reflux management system: confirmed safety and efficacy now at 4 years. Surg Endosc. 2012;26:2944–2949. doi: 10.1007/s00464-012-2289-1.
    1. Bonavina L, Saino G, Bona D, Sironi A, Lazzari V. One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg. 2013;217:577–585. doi: 10.1016/j.jamcollsurg.2013.04.039.
    1. Ganz RA, Peters JH, Horgan S, Bemelman WA, Dunst CM, Edmundowicz SA, Taiganides PA. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med. 2013;368:719–727. doi: 10.1056/NEJMoa1205544.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe